Hemolytic anemia is a condition in which red blood cells are destroyed faster than your bone marrow can replace them. Normal red blood cells live about 120 days, but in hemolytic anemia, that lifespan is significantly shortened, leaving your body without enough healthy cells to carry oxygen to your tissues. The condition can be inherited or acquired at any point in life, and its severity ranges from mild and barely noticeable to life-threatening.
How Red Blood Cells Are Destroyed
Red blood cell destruction in hemolytic anemia happens in one of two ways, and the distinction matters because it affects which symptoms show up and how doctors identify the cause.
In extravascular hemolysis, the spleen filters out and destroys abnormal red blood cells. Healthy red blood cells are flexible enough to squeeze through the spleen’s narrow passages, but cells that are misshapen, too rigid, or coated in antibodies get trapped and broken down. This is what happens in sickle cell disease, where red blood cells become crescent-shaped and can’t pass through, and in hereditary spherocytosis, where the cells are abnormally round and stiff. This type of destruction tends to cause an enlarged spleen over time.
In intravascular hemolysis, red blood cells rupture directly inside your blood vessels. This releases their contents, including hemoglobin, straight into the bloodstream. It happens in conditions where cells are physically sheared apart (by a mechanical heart valve, for example) or attacked by the immune system’s complement proteins. Because free hemoglobin spills into the blood, intravascular hemolysis is more likely to cause dark or reddish urine and can be harder on the kidneys.
Inherited Causes
Some forms of hemolytic anemia are present from birth, caused by genetic defects that affect the structure or function of red blood cells. The three most common inherited types target different parts of the cell.
Sickle cell disease results from a mutation in the gene for hemoglobin, the oxygen-carrying protein inside red blood cells. The altered hemoglobin causes cells to deform into a rigid sickle shape under low-oxygen conditions. These misshapen cells get stuck in small blood vessels and are rapidly cleared by the spleen. Over 1,200 genetic alterations affecting the human globin genes have been identified, which explains why the severity of hemoglobin disorders varies so widely between individuals.
Hereditary spherocytosis involves defects in the proteins that form the red blood cell’s flexible membrane. Mutations in at least five different genes can weaken this structural scaffolding, causing the normally disc-shaped cell to balloon into a sphere. Spherical cells can’t deform to pass through the spleen’s filtering system, so they’re trapped and destroyed.
G6PD deficiency is the most common red blood cell enzyme disorder in the world, affecting an estimated 400 million people. It follows an X-linked inheritance pattern, meaning it primarily affects males. The enzyme G6PD protects red blood cells from oxidative damage. Without enough of it, certain triggers can cause a sudden burst of cell destruction. At least 186 different mutations in the G6PD gene have been documented, most of them single-letter changes in the DNA code.
Triggers for G6PD Deficiency
People with G6PD deficiency can go long stretches without symptoms, then experience a rapid hemolytic episode after exposure to an oxidative trigger. The most well-known dietary trigger is fava beans. Medications to avoid include the antibiotic nitrofurantoin, the antimalarial drug primaquine, the urinary pain reliever phenazopyridine, dapsone (used for certain skin conditions), methylene blue, rasburicase, and several sulfa-based drugs. Infections can also trigger episodes because the body’s inflammatory response generates oxidative stress.
Acquired Causes
Hemolytic anemia that develops later in life is most often driven by the immune system, medications, infections, or mechanical forces. The immune-mediated forms are divided by the type of antibody involved and the temperature at which it becomes active.
Warm autoimmune hemolytic anemia is the most common autoimmune type. The antibodies involved (primarily IgG) bind to red blood cells at normal body temperature, around 37°C (98.6°F), flagging them for destruction by the spleen. About half of cases have no identifiable cause. The other half are linked to an underlying condition, such as lupus or a lymphoma, or to certain medications.
Cold agglutinin disease involves a different class of antibody (IgM) that attaches to red blood cells at cooler temperatures, typically below 30°C (86°F). This means hemolysis worsens with cold exposure, particularly in the fingers, toes, ears, and nose where blood cools as it circulates near the skin. Some cases are triggered by infections like mononucleosis or mycoplasma pneumonia and resolve on their own. Others are chronic, driven by an abnormal clone of immune cells that continuously produces the cold-reactive antibody.
Drug-induced hemolytic anemia occurs when medications provoke the immune system to attack red blood cells. Cephalosporin antibiotics are the most common cause. Other medications linked to this reaction include penicillin and its derivatives, NSAIDs, levodopa, levofloxacin, methyldopa, and nitrofurantoin. The anemia typically resolves after the offending drug is stopped.
Symptoms to Recognize
The classic triad of hemolytic anemia is anemia (fatigue, weakness, shortness of breath), jaundice (yellowing of the skin and eyes), and an enlarged spleen. Jaundice occurs because when red blood cells break down, they release bilirubin, a yellow pigment that builds up in the blood. Total bilirubin levels rarely exceed 5 mg/dL when liver function is normal, except during acute crises like a sickle cell episode.
Dark or cola-colored urine is another hallmark, especially in intravascular hemolysis, where free hemoglobin passes through the kidneys. Some people also develop pigmented gallstones over time because the chronic excess of bilirubin crystallizes in the gallbladder. The onset can be gradual in chronic forms or alarmingly fast in acute episodes, where hemoglobin drops rapidly over hours to days.
How It’s Diagnosed
Diagnosis involves blood tests that look for indirect evidence of red blood cell destruction. Three markers form the core of a hemolysis workup. Lactate dehydrogenase (LDH), an enzyme released from broken cells, rises. Haptoglobin, a protein that normally mops up free hemoglobin in the blood, drops because it gets used up during active hemolysis. Indirect bilirubin rises as the liver processes the debris from destroyed cells.
A blood smear under the microscope can reveal telltale cell shapes: sickle cells, spherocytes, or fragmented cells called schistocytes that suggest mechanical destruction.
The Direct Antiglobulin Test, commonly called the Coombs test, is key to distinguishing immune-mediated causes from everything else. It detects antibodies or complement proteins stuck to the surface of red blood cells. A positive result, defined as visible clumping of cells or microscopic aggregates of at least 3 to 5 cells, points toward an autoimmune or drug-induced cause. A negative Coombs test steers the investigation toward inherited disorders, mechanical destruction, or infections.
Treatment Approaches
Treatment depends entirely on the underlying cause. For inherited forms like sickle cell disease or hereditary spherocytosis, management is often lifelong and focused on preventing crises, managing symptoms, and sometimes surgical removal of the spleen to reduce the site of red blood cell destruction.
For autoimmune hemolytic anemia, corticosteroids are the standard first-line treatment. They produce a response in more than 80% of patients, typically within 2 to 3 weeks. When steroids aren’t enough or the anemia relapses, rituximab (a targeted immune therapy given as an infusion) has become the preferred second-line option, with effectiveness in about 80% of patients and a median time to response of 3 to 6 weeks. Responses to rituximab tend to last around 2 years.
Spleen removal was historically the go-to second-line treatment, with success rates of 70% to 80%, but it’s now reserved for later in the treatment sequence. Only about 10% to 15% of autoimmune hemolytic anemia patients undergo splenectomy today. For severe, rapidly worsening cases, blood transfusions and plasma exchange may be used to stabilize the patient while other treatments take effect.
For drug-induced cases, stopping the offending medication is usually sufficient. For cold agglutinin disease, avoiding cold exposure is a practical first step, though chronic cases driven by abnormal immune cell clones may require targeted therapy.
Long-Term Complications
Chronic hemolytic anemia carries health risks beyond the anemia itself. The constant breakdown of red blood cells floods the body with free hemoglobin, which scavenges nitric oxide, a molecule your blood vessels need to stay relaxed and open. Over time, this depletion of nitric oxide leads to stiffening and narrowing of blood vessels, raising the risk of pulmonary hypertension, a serious condition where blood pressure in the lung arteries climbs dangerously high. Pulmonary hypertension has become recognized as a major cause of illness and death in sickle cell disease and other chronic hemolytic conditions.
The same process promotes blood clotting. Chronic hemolysis increases platelet activation and the generation of clotting factors, raising the risk of dangerous blood clots. Pigmented gallstones are common with any chronic hemolytic anemia because the liver can’t keep up with processing all the excess bilirubin. Iron overload is another concern, particularly in people who require frequent blood transfusions, as each unit of transfused blood adds iron that the body has no efficient way to excrete.